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Abstract
Human tissue inflammation is terminated, at least in part, by the death of inflammatory neutrophils by apoptosis. The
regulation of this process is therefore key to understanding and manipulating inflammation resolution. Previous data have
suggested that the short-lived pro-survival Bcl-2 family protein, Mcl-1, is instrumental in determining neutrophil lifespan.
However, Mcl-1 can be cleaved following caspase activity, and the possibility therefore remains that the observed fall in Mcl-
1 levels is due to caspase activity downstream of caspase activation, rather than being a key event initiating apoptosis in
human neutrophils. We demonstrate that apoptosis in highly purified neutrophils can be almost completely abrogated by
caspase inhibition with the highly effective di-peptide caspase inhibitor, Q-VD.OPh, confirming the caspase dependence of
neutrophil apoptosis. Effective caspase inhibition does not prevent the observed fall in Mcl-1 levels early in ultrapure
neutrophil culture, suggesting that this fall in Mcl-1 levels is not a consequence of neutrophil apoptosis. However, at later
timepoints, declines in Mcl-1 can be reversed with effective caspase inhibition, suggesting that Mcl-1 is both an upstream
regulator and a downstream target of caspase activity in human neutrophils.
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Introduction
We are protected against infectious disease by a range of
mechanisms, including innate immune cells such as neutrophils
and macrophages. Neutrophils have the shortest lifespan of any
healthy cell, and this brief lifespan limits pro-inflammatory
functions of the neutrophil [1]. At sites of infection or potential
infection (tissue injury), neutrophils are thought to have an
extended functional lifespan [2], allowing the body to more
evenly match neutrophil numbers with the numbers of rapidly
dividing bacteria. Survival signals received by the neutrophils,
such as cytokines (e.g. GM-CSF [3]), bacterial products [4] and
hypoxia [5] act to profoundly delay neutrophil lifespan in in vitro
cultures, which are thought to mimic the in vivo behaviour of
neutrophils. Importantly, the downstream molecular signals by
which these survival signals impinge on the pathways governing
the normally short lifespan of the neutrophil are incompletely
known.
It is generally accepted that multidomain pro-survival Bcl-2
family proteins are important in regulating neutrophil longevity
[6]. Mcl-1 [7] and, to a lesser extent, A1 [8] have been shown to
be important for maintaining neutrophil survival, and have
additionally been implicated in signalling extended neutrophil
lifespan in response to a variety of stimuli including cytokines [9],
elevated cAMP [10] and hypoxia [11,12]. A key role for Mcl-1 is
further supported by the decreased survival seen in myeloid cells
treated with antisense oligonucleotides against Mcl-1 [12,13].
Increased Mcl-1 levels have also been reported in inflammatory
settings in vivo: in freshly isolated neutrophils from Crohns disease
patients [14]; and in animal models of endotoxaemia [15].
Importantly, therapeutic strategies using CDK inihibitors or
Lipoxins to target neutrophils appear to act via modulation of
Mcl-1 [16–18].
Mcl-1 is regulated in complex ways, with multiple isoforms
generated by alternative splicing present in human neutrophils
[19]. In addition, Mcl-1 is known to be proteolytically cleaved
downstream of caspase activity, leading to multiple protein
products on Western blotting [20]. Caspase activity has been
demonstrated in human neutrophils, but the role this plays in
determining the timing of neutrophil death is controversial, with
apparently conflicting data in the literature [21–24].
Some observers have surmised that falling Mcl-1 levels
initiate caspase activation [6] by removal of inhibition of pro-
apoptotic Bcl-2 family proteins, such as Bim. In this model,
BH-3 only proteins act to cause cytochrome c release from the
mitochondria, and hence Apaf-1 dependent caspase activation.
Published data show an inverse relationship between Mcl-1
levels and degree of apoptosis in all neutrophil populations
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studied. This could either indicate that falling Mcl-1 levels
trigger apoptosis, or Mcl-1 is degraded by apoptotic proteases
– a well described phenomenon [20,25]. We hypothesised that
new and potent caspase inhibitors might allow us to dissociate
falls in Mcl-1 levels from rates of neutrophil apoptosis. We
show that the irreversible dipeptide caspase inhibitor Q-
VD.OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophe-
noxy]-methylketone) profoundly inhibits neutrophil apoptosis,
and that Mcl-1 levels drop in advance of apoptosis, even in the
presence of caspase inhibition. At later timepoints, however,
Mcl-1 levels are inversely proportional to the fraction of
apoptotic neutrophils in the population. These data suggest
Mcl-1 is both a regulator and a downstream target of caspase
activation in the neutrophil.
Methods
Ethics Statement
Peripheral venous blood was taken from healthy volunteers in
accordance with the specific approval of the South Sheffield
Research Ethics Committee (reference number: STH13927). Fully
informed written consent was obtained, and all clinical investiga-
tion was conducted according to the principles expressed in the
Declaration of Helsinki.
Reagents
All reagents including zVAD.fmk were from Sigma-Aldrich
(Poole, UK) unless otherwise stated. Q-VD.OPh was from R&D
systems (Abingdon, UK). Recombinant human GMCSF was from
Peprotech (London, UK).
Purification of peripheral blood neutrophils
Percoll blood preparations were performed as previously
described [26]. Briefly, Dextran sedimented neutrophils were
separated by centrifugation over a plasma-Percoll column, washed
and resuspended in RPMI, with 10% Foetal Calf Serum
(Invitrogen) and 100 U/ml of Penicillin and 100 mg/ml Strepto-
mycin (Life Technologies) at 56106 neutrophils per ml. The
OptiPrepTM (Axis-Shield, Upton, Huntingdon, UK) method of
neutrophil isolation is a modification of the Percoll method using
an OptiPrepTM gradient rather than Percoll. Cells isolated with
the OptiPrepTM method were further purified by negative
magnetic selection using a custom cocktail (Stemcell Technologies,
Vancouver, Canada) [4]. Cytospin preparations fixed with 100%
methanol and stained with Quick-Diff (Gentaur) were counted
using a TE-2000U microscope (Nikon, Tokyo, Japan) at 6900
magnification. Neutrophil, eosinophil and PBMC numbers were
counted, based on their characteristic appearance. A total of 500
cells were counted per sample, and the proportion of neutrophils
Figure 1. The caspase inhibitor Q-VD.OPh profoundly inhibits neutrophil apoptosis. A,B) Neutrophils were cultured for A) 8 hours, and B)
20 hours with and without the pan-caspase inhibitors zVAD.fmk and Q-VD.OPh with a DMSO vehicle control (n = 4). Q-VD.OPh dramatically decreased
neutrophil apoptosis from 10 nM, whereas no effects of zVAD were seen below 100 mM. *P,0.05, **P,0.01, ***p,0.001 for comparison of Q-VD vs
zVAD, one way ANOVA with Bonferroni’s post-test correction, comparing all values. C) Cytospin preparation of neutrophils in control conditions after
20 hours. Apoptotic cells are clearly visible by their condensed nuclei. D) Cytospin preparation of neutrophils cultured with Q-VD.OPh after 20 hours.
No apoptotic cells can be seen and neutrophils exhibit the classic polymorphic nuclear morphology of a healthy neutrophil. Images were taken using
a 606 Plan Apo Oil immersion NA1.40, Nikon, with 1.56magnification on a Nikon TE2000U.
doi:10.1371/journal.pone.0015768.g001
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to eosinophils and PBMC was noted. For assessment of apoptosis
300 neutrophils were counted by a blinded, trained observer.
Detection of neutrophil Mcl-1 by western blot analysis
Neutrophils were resuspended in ice-cold phosphate buffered
saline (PBS) solution and centrifuged at 300 g for 2 minutes.
Neutrophils were then resuspended in 30 ml of ice cold buffer
(50 mM Tris, 50 mM NaF, 50 mM b-glycerophosphate, 10 mM
Sodium Orthovanadate) with 1:100 protease inhibitor cocktail set
IV and 1 mM PMSF. This was immediately followed by the
addition of 30 ml ice cold phosphatase lysis buffer (buffer above
plus 1 in 50 Triton-X100), also with 1:100 protease inhibitor
cocktail set IV and 1 mM PMSF. 60 ml of 2xSDS lysis buffer
(1 M DTT, 20% SDS, Glycerol, 0.5 M pH 6.8 Tris-HCl, 0.2%
Bromophenol Blue) with 1:50 EDTA free protease inhibitor
cocktail was then added and the sample was heated at 95uC for
10 minutes. The samples were frozen at 280uC until required for
analysis. Western blotting was performed according to standard
protocols [27], using Protean 2 gel assembly (Bio-Rad, Berkeley,
CA). Protein samples from 1 to 1.56106 neutrophils were run
alongside 10 ml of full-range rainbow molecular weight ladder
(GE Healthcare Life Sciences, Uppsala, Sweden), and transferred
to HybondTM-P PVDF membrane (GE Healthcare Life Sciences)
using a Trans-BlotH semi dry blotter (Bio-Rad). Antibody
incubations were overnight at 4uC (primary) and 60 minutes at
room temperature (secondary).
Quantification of western blot band density
Films were scanned using an Epson flatbed scanner in TIFF
format and densitometry was performed using Image J [28],
according to online instructions [29]. Band density was given as
a percentage of the overall density of all bands, making the
measurement relative. To eliminate loading discrepancies, this
measurement was then given as a percentage of the density of
the actin control band, to give the final relative protein
expression.
Figure 2. At early timepoints, Mcl-1 levels fall even in the presence of highly effective caspase inhibition. Neutrophils were cultured 6
caspase inhibitor, Q-VD.OPh (QVD), 6 DMSO (vehicle control) for 8 hours. Neutrophil apoptosis rates were determined by cytospin analysis (upper
panel), and relative Mcl-1 levels determined using western blotting for 3 independent experiments (middle panel). Q-VD.OPh significantly reduced
rates of apoptosis. In the presence of Q-VD.OPh, amounts of Mcl-1 were significantly lower in control neutrophil lysates compared to lysates from
GMCSF treated cells (*p,0.001 for control vs GMCSF, one way ANOVA with Bonferroni’s post-test correction, n = 3.)
doi:10.1371/journal.pone.0015768.g002
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Results and Discussion
Neutrophil apoptosis is profoundly inhibited by the
caspase inhibitor Q-VD.OPh
The caspase dependency of neutrophil apoptosis remains
controversial. Several publications have indicated that caspase
inhibitors are ineffective in blocking neutrophil apoptosis, and
have concluded from this that caspase independent apoptosis
pathways are implicated in limiting neutrophil lifespan
[22,23,30]. A recent review reflected this uncertainty [24].
However, our own work has supported a role for caspase
inhibitors in delaying neutrophil apoptosis [21]. In order to test
whether the differences in the literature are due to the different
caspase inhibitors and concentrations used, we performed a
detailed dose response analysis of the most commonly used
caspase inhibitor in neutrophil studies, zVAD.fmk against a new
dipeptide inhibitor which we had found to be profoundly
effective in delaying apoptosis in neutrophils, Q-VD.OPh. This
pan-caspase inhibitor, like zVAD.fmk, binds irreversibly to the
active site of activated caspases. It is non-toxic to cells, highly
cell permeable and has been found to be more effective at
reducing apoptosis than zVAD.fmk [31]. zVAD.fmk does not
inhibit neutrophil apoptosis at concentrations below 100 mM
(Figure 1), suggesting the ineffectiveness of zVAD.fmk in
previously published studies may be a feature of the higher
concentrations required in neutrophils compared to other cell
types. In contrast, Q-VD.OPh is highly effective at blocking
neutrophil apoptosis at concentrations as low as 100 nM, and
begins to have an effect at 10 nM. Therefore, these data present
Q-VD.OPh as a highly effective neutrophil caspase inhibitor
and confirm the requirement for caspase activity in neutrophil
apoptosis.
Figure 3. At late timepoints, Mcl-1 levels are maintained by highly effective caspase inhibition. Neutrophils were cultured 6 caspase
inhibitor, Q-VD.OPh (QVD), 6 DMSO (vehicle control) for 20 hours. Neutrophil apoptosis rates were determined by cytospin analysis (upper panel),
and relative Mcl-1 levels determined using western blotting for 3 independent experiments (middle panel) as previously shown. In the presence of Q-
VD.OPh, there was no significant difference in levels of Mcl-1 in control neutrophil lysates compared to lysates from GMCSF treated cells (*p,0.001
for control vs GMCSF, one way ANOVA with Bonferroni’s post-test correction, n = 3.)
doi:10.1371/journal.pone.0015768.g003
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Q-VD.OPh differs from other caspase inhibitors in three
distinct ways that might contribute to its increased potency and
efficacy in inhibiting neutrophil apoptosis. As a dipeptide inhibitor
it is smaller and may pass more easily into cells. The process of cell
penetration may be further enhanced by the addition of the N-
terminal quinolyl group. Finally, the carboxy terminal O-Phenoxy
group replaces the fluoromethylketone group, and has been
reported as reducing toxicity [31].
At early timepoints, Mcl-1 levels fall even in the presence
of highly effective caspase inhibition
One of the key unresolved questions in neutrophil biology is the
relationship between neutrophil apoptosis and falling Mcl-1 levels.
Mcl-1 levels fall as apoptosis progresses, and survival signals that
prolong neutrophil lifespan increase Mcl-1 levels [9]. However,
Mcl-1 is also a well-recognised caspase substrate in various cell
types [20,25,32,33], including neutrophils in certain circumstances
[34]. Therefore it is important to identify whether Mcl-1
degradation is the signal for apoptosis and caspase activity, or
whether it is degraded downstream of caspases in neutrophils.
Previous studies have used lower doses of caspase inhibitors in the
presence of cyclohexamide [35]. We therefore tested the ability of
highly effective caspase inhibition to maintain Mcl-1 levels in
neutrophils in the absence of protein synthesis inhibitors. Mcl-1
levels at 8 hours were not altered by highly effective caspase
inhibition with Q-VD.OPh (Figure 2), and GM-CSF was able to
significantly increase Mcl-1 levels, back to levels comparable to
those in freshly isolated neutrophils (Figure S1). These data
confirm previous suggestions that, at early timepoints, the
observed reduction in Mcl-1 levels is an upstream event in
initiating caspase activity and apoptosis.
At later timepoints, Mcl-1 degradation is downstream of
caspase activation in neutrophils
Rates of apoptosis are low at early timepoints, and effective
caspase inhibition has profound and long-lasting effects, still
completely blocking neutrophil apoptosis at 20 hours. We therefore
investigated the effect of complete blockade of caspase dependent
neutrophil apoptosis with Q-VD.OPh on Mcl-1 levels at later
timepoints. Mcl-1 levels were increased in neutrophils treated with
Q-VD.OPh alone, to the same level as GMCSF treated neutrophils
and freshly isolated neutrophils (Figure S1), suggesting that by
20 hours the observed decrease in Mcl-1 levels are in part a
consequence of caspase activation, and caspase-dependent Mcl-1
Figure 4. GM-CSF increased Mcl-1 levels in standard purity and highly purified neutrophils between 8 and 20 hours. A. Rates of
apoptosis (top) and Mcl-1 expression 6 GM-CSF as determined by western blot analysis in neutrophils isolated using the Percoll method. n = 3
independent experiments from different donors. *P,0.05, *** p,0.001, one-way ANOVA, with Bonferroni’s post-test correction for multiple
comparisons. B. Rates of apoptosis (top) and Mcl-1 expression 6 GM-CSF as determined by western blot analysis in neutrophils isolated using the
OptiPrep (+NMS) method. n = 3 independent experiments from different donors. *P,0.05 one-way ANOVA, with Bonferroni’s post-test correction for
multiple comparisons.
doi:10.1371/journal.pone.0015768.g004
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degradation (Figure 3). In other words, at later timepoints the
decrease in Mcl-1 levels appears to be a consequence of apoptosis,
rather than a controlling factor. This would imply that GM-CSF is
able modulate apoptosis via Mcl-1 independent mechanisms, as also
suggested by the ability of GM-CSF to delay neutrophil apoptosis in
mice with a myeloid specific Mcl-1 defect [7].
Since Mcl-1 is a known caspase substrate in some cells, it might
be expected that the increase in Mcl-1 levels induced by caspase
inhibition occurs via directly protecting Mcl-1 from caspase
cleavage. However, unlike other groups [20], we did not detect
Mcl-1 caspase-cleavage products in our control samples using the
same anti-Mcl-1 antibody. The additional bands identified were
larger than Mcl-1 caspase cleavage fragments and are thought to
be Mcl-1 splice variants [19]. Expression of these bands, both in
absolute terms and as a proportion of full-length Mcl-1, was not
significantly altered, even by complete suppression of caspase-
dependent cell death by Q-VD.OPh (Figures 2 and 3). Therefore,
this suggests that Mcl-1 degradation at 20 hours might be
mediated downstream of caspase activation, possibly by calpains
[36], rather than by caspases directly.
GM-CSF acts directly on neutrophils to increase Mcl-1
protein levels
Isolation of granulocytes from other haematological cells is
usually based on density, with separation using a discontinuous
plasma/PercollTM density gradient being a widely used method
[26,37]. This method usually results in high levels of granulocyte
purity, with 1–2% contaminating Peripheral Blood Mononuclear
Cells (PBMC). Density-based separation methods cannot distin-
guish between eosinophils and neutrophils, therefore overall
neutrophil purity is dependent on donor eosinophil numbers.
Contaminating mononuclear cells are able to profoundly influence
the behaviour of neutrophils in culture [38], and may contribute
disproportionate levels of certain proteins to western blotting
analysis. It has previously been shown that, unlike LPS, GM-CSF
delay of neutrophil apoptosis is not dependent on contaminating
monocytes [39]. However, the response of Mcl-1 to survival signals
such as GM-CSF might relate to either induction of Mcl-1 in
neutrophils by unspecified monocyte factors, or to direct monocyte
contamination of protein lysates. Levels of Mcl-1 and modulation
by GM-CSF were therefore assessed in standard purity neutrophil
preparations and in ultrapure neutrophil preparations (with
negative magnetic selection), resulting in small and no PBMC
contamination respectively (1.4%60.48 n=6 vs 0.060.0 n= 4).
These cells were cultured with and without GM-CSF for 8 and
20 hours, after which apoptosis rates were determined by cytospin
analysis, and compared to Mcl-1 levels assessed by comparative
densitometry of three independent western blot analyses. In
standard purity neutrophil cultures, Mcl-1 levels declined between
8 and 20 hours in control neutrophils, as has been previously
shown [9]. Mcl-1 was upregulated in GM-CSF stimulated
neutrophils compared to control cells at both 8 and 20 hours,
showing statistical significance by 20 hours in Percoll purified
samples (Figure 4A). Reduction in Mcl-1 levels over time and
inhibition of this reduction by GMCSF are seen in the ultrapure
preparations at a comparable level (Figure 4B), suggesting that the
effects of GMCSF on Mcl-1 levels are not due to the influence of
contaminating monocytes.
Conclusion
Regulation of Mcl-1 levels within human neutrophils has key
effects on neutrophil survival in vivo [7] and in vitro [9]. Mcl-1 levels
initially fall during neutrophil culture in vitro independently of
neutrophil apoptosis, and these data support the assertion that this fall
in Mcl-1 levels may be the initiating event of neutrophil apoptosis.
However, by 20 hours of culture, Mcl-1 levels reflect degree of
apoptosis, suggesting that at these timepoints Mcl-1 levels are
predominantly regulated by degradation downstream of caspases.
Supporting Information
Figure S1 Mcl-1 levels fall between 0 and 8 hours in
culture and GM-CSF prevents this reduction. A. Neutro-
phils were either lysed at time 0 or cultured 6 GM-CSF for
8 hours and relative Mcl-1 levels determined using western
blotting. Mcl-1 levels fall significantly between time 0 and time 8
lysates (*p,0.001 for control vs 8 hours - GMCSF, one way
ANOVA with Bonferroni’s post-test correction, n= 2.). GM-CSF
treatment maintains Mcl-1 levels.
(TIF)
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